Bristol-Myers Squibb (BMY): Rega marang bathi kanthi panyesuaian wutah

Simbol lan logo merek Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (BMY) maintains a strong reputation in hematology despite patent cliff risks, as illustrated by the PEG ratio. The value of 0.00 captures the level of this metric. The company relies on a powerful R&D center and massive budgets to retain scientists. High clinical trial costs and the acquisition of startups create significant barriers to entry for new players.

Bristol-Myers Squibb Co. - Pangali PEG BMY (periode 04.07.2022 - 16.11.2026)

Rincian metrik lan analitis perusahaan BMS (BMY)

Analisis umum perusahaan:Bristol-Myers Squibb
Barang utama Bristol Myers Squibb Company

The closed-loop treatment cycle and patent protection of Bristol-Myers Squibb (BMY) oncology drugs create a sustainable barrier for competitors, ensuring stable profit dynamics. An analysis of the peg_co ratio allows for a comparison of the current market value of shares with the pace of business expansion: a value below one signals that capital is undervalued relative to growth prospects, which is critical for identifying undervalued assets.